LEGN - Legend Biotech Corp

QQQ $ 441.71 $ 1.04 (0.24 %)

DIA $ 395.04 $ 1.18 (0.3 %)

SPY $ 520.76 $ 0.67 (0.13 %)

TLT $ 90.14 $ -0.51 (-0.56 %)

GLD $ 218.73 $ 1.76 (0.81 %)

Previous Close

$ 43.24

Open

$ 45.74

Bid

$ 43.20 x 100

Ask

$ 43.24 x 200

Day's Range

$ 42.98 - $ 45.74

52 Week Range

$ 42.08 - $ 77.32

Volume

887,324

Average Volume

Market Cap

15.73B

Beta (5Y Monthly)

$ 0.60

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
No Data found

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

HC Wainwright & Co. Reiterates Buy on Lege...
05/09/2024 18:56:45

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $87 price t...

HC Wainwright & Co. Reiterates Buy on Lege...
04/23/2024 10:19:23

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $87 price t...

$legend-biotech-announces-carvykti-approved-by-the-european-commission-for-second-line-treatment-of-patients-with-relapsed-and-refractory-multiple-myeloma$

Legend Biotech Announces Carvykti Approved...
04/22/2024 17:09:33

New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapseLegend Bi...

fda-mandates-boxed-warning-for-bristol-myers-johnson--johnson-car-t-based-blood-cancer-therapies

FDA Mandates "Boxed Warning" For Bristol M...
04/19/2024 13:28:52

Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—t...

Analyst Ratings For Legend Biotech
04/17/2024 14:01:36

Scotiabank Upgrades Legend Biotech to Sect...
04/17/2024 12:20:16

Scotiabank analyst George Farmer upgrades Legend Biotech (NASDAQ:LEGN) from Sector Perform to Sector Outperform and maintain...

HC Wainwright & Co. Reiterates Buy on Lege...
04/16/2024 17:10:10

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $87 price t...

Legend Biotech Earlier Announced CARVYKTI ...
04/16/2024 15:42:49

johnson--johnsons-carvykti-stands-ahead-of-bristol-myers-rival-blood-cancer-therapy-with-fda-approval-for-wider-population

Johnson & Johnson's Carvykti Stands Ahead ...
04/08/2024 18:19:35

FDA approves Johnson & Johnson's Carvykti, a BCMA-targeted therapy for relapsed or refractory multiple myeloma patients...

On Friday April 5, 2024, Legend Biotech Re...
04/08/2024 07:42:07

New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapseLegend Bi...

Cantor Fitzgerald Initiates Coverage On Le...
04/03/2024 11:47:47

Cantor Fitzgerald analyst Rick Bienkowski initiates coverage on Legend Biotech (NASDAQ:LEGN) with a Overweight rating and an...

Unveiling 9 Analyst Insights On Legend Bio...
04/01/2024 12:01:27

HC Wainwright & Co. Reiterates Buy on Lege...
04/01/2024 10:12:24

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $87 price t...

genscript-losses-shrink-on-strong-growth-for-cancer-cell-therapy

GenScript Losses Shrink On Strong Growth F...
03/20/2024 15:30:12

Key Takeaways: GenScript’s cell therapy revenue grew by 143.7% last year as a CAR-T cell therapy developed by its Legend Bio...

Legend Biotech Filed For Mixed Shelf Offer...
03/19/2024 12:00:19

UBS Maintains Buy on Legend Biotech, Raise...
03/18/2024 14:18:30

UBS analyst Ashwani Verma maintains Legend Biotech (NASDAQ:LEGN) with a Buy and raises the price target from $76 to $81.

fda-adcomm-favors-expanded-use-of-johnson--johnson-bristol-myers-car-t-therapies-for-type-of-blood-cancer

FDA Adcomm Favors Expanded Use Of Johnson ...
03/18/2024 14:16:36

FDA's adcomm recommends expanded use of Bristol Myers Squibb's Abecma for triple-class exposed relapsed or refractory m...

HC Wainwright & Co. Reiterates Buy on Lege...
03/18/2024 10:39:23

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $87 price t...

$legend-biotech-announces-fda-oncologic-drugs-advisory-committee-recommended-carvykti-for-treatment-of-patients-with-relapsedrefractory-multiple-myeloma$

Legend Biotech Announces FDA Oncologic Dru...
03/15/2024 19:16:15

fda-to-review-two-cell-therapies-for-multiple-myeloma-this-week---johnson--johnson-and-bristol-myers

FDA To Review Two Cell Therapies For Multi...
03/13/2024 17:43:59

Join the FDA's Oncologic Drugs Advisory Committee on March 15th to review Johnson & Johnson/Legend Biotech's Carvyk...